MedWatch

Genmab CEO: Arbitration might be concluded in 2021

The legal strife between Genmab and its partner Janssen may be settled this year, according to Genmab CEO Jan van de Winkel, although he is not sure about the timing.

Photo: PR / Genmab

Genmab's dispute with its business partner over blockbuster drug Darzalex, the Johnson & Johnson-owned Janssen Biotech, may draw out.

"We can say very little. The timing is naturally uncertain, but you're summarizing it quite well. Yes, it may be decided in 2021, but it potentially could be in 2022," said Genmab CEO Jan van de Winkel on Wednesday at a teleconference.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Coloplast upgrades growth expectations following acquisition

Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.

Demant's surgical division loses president of 13 years

Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.

Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

Further reading

Related articles

Latest news

See all jobs